About: Metelimumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006.

Property	Value
dbo:abstract	ميتيليموماب هو جسم مضاد وحيد النسيلة بشري كانت تجرى عليه التجارب السريرية لدراسة استخدامه في علاج تصلب الجلد الجهازي المنتشر لكنها ألغيت بسبب تفضيل فريسوليموماب الذي تطوره . (ar) Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006. (en)
dbo:casNumber	272780-74-2
dbo:fdaUniiCode	4AR6718OL0
dbo:wikiPageID	9132560 (xsd:integer)
dbo:wikiPageLength	4397 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1030895316 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Cambridge_Antibody_Technology dbr:Fresolimumab dbr:Genzyme dbr:Monoclonal_antibody dbr:Phage_display dbc:Monoclonal_antibodies dbr:Systemic_scleroderma dbr:Sclerosis_(medicine) dbr:Scleroderma dbr:TGF_beta_1 dbr:IgG4 dbr:TGF_beta
dbp:atcPrefix	none (en)
dbp:casNumber	272780 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:legalStatus	Investigational (en)
dbp:mabType	mab (en)
dbp:source	u (en)
dbp:target	dbr:TGF_beta_1
dbp:type	mab (en)
dbp:unii	4 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458283946 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Monoclonals_for_immune_system dbt:Immunosuppressants dbt:TGFβ_receptor_superfamily_modulators dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:comment	ميتيليموماب هو جسم مضاد وحيد النسيلة بشري كانت تجرى عليه التجارب السريرية لدراسة استخدامه في علاج تصلب الجلد الجهازي المنتشر لكنها ألغيت بسبب تفضيل فريسوليموماب الذي تطوره . (ar) Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006. (en)
rdfs:label	ميتيليموماب (ar) Metelimumab (en)
owl:sameAs	freebase:Metelimumab yago-res:Metelimumab wikidata:Metelimumab dbpedia-ar:Metelimumab dbpedia-vi:Metelimumab https://global.dbpedia.org/id/4rZ2P dbr:Metelimumab
prov:wasDerivedFrom	wikipedia-en:Metelimumab?oldid=1030895316&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Metelimumab
is dbo:wikiPageRedirects of	dbr:CAT-192
is dbo:wikiPageWikiLink of	dbr:Cambridge_Antibody_Technology dbr:CAT-192 dbr:Fresolimumab dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Met
is foaf:primaryTopic of	wikipedia-en:Metelimumab